{"nctId":"NCT02460978","briefTitle":"Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes","startDateStruct":{"date":"2015-07-08","type":"ACTUAL"},"conditions":["Type 1 Diabetes Mellitus"],"count":815,"armGroups":[{"label":"Dapagliflozin 5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Dapagliflozin"]},{"label":"Dapagliflozin 10 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Dapagliflozin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo for dapagliflozin"]}],"interventions":[{"name":"Dapagliflozin","otherNames":[]},{"name":"Placebo for dapagliflozin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of Type 1 Diabetes mellitus (T1DM)\n* Central laboratory C-peptide \\< 0.7 ng/ml (0.23 nmol/L)\n* Insulin use for at least 12 months per patient reported or medical records\n* Method of insulin administration (MDI or CSII) must have been unchanged for at least 3 months prior to screening\n* Subjects must be on a total insulin dose of ≥ 0.3 U/kg/day for at least 3 months prior to screening\n* If on MDI insulin administration, subject must be on ≥ 3x injections per day\n* Screening Visit: Central laboratory HbA1c ≥ 7.7% and ≤ 11.0%\n* Body mass index (BMI) ≥ 18.5 kg/m2\n\nExclusion Criteria:\n\n* History of Type 2 Diabetes mellitus (T2DM) or maturity onset diabetes of the young (MODY), pancreatic surgery, or chronic pancreatitis that could result in decreased beta cell capacity\n* Taking any non-insulin antihyperglicemic agent within 1 month prior to screening\n* Taking GLP-1 receptor agonist within 2 months prior to screening for once weekly administration and within 1 month prior to screening for once or twice daily administration\n* Taking metformin and/or thiazolidinediones within 2 months prior to screening\n* History of diabetes ketoacidosis requiring medical intervention within 1 month prior to screening\n* History of hospital admission for glycemic control (either hyperglycemia or hypoglycemia) within 1 month prior to screening\n* Frequent episodes of severe hypoglycemia (more than one episode requiring medical assistance, emergency care), and/or glucagon therapy administered by a third-party individual within 1 month prior to screening\n* History of Addison's disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Adjusted Mean Change From Baseline in HbA1c at Week 24","description":"To compare the change from baseline in HbA1c between dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.34","spread":null},{"groupId":"OG001","value":"-0.39","spread":null},{"groupId":"OG002","value":"0.03","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Percentage Change From Baseline in Total Daily Insulin Dose at Week 24","description":"To compare the percent change from baseline in total daily insulin dose with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.73","spread":null},{"groupId":"OG001","value":"-9.05","spread":null},{"groupId":"OG002","value":"2.29","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Percentage Change From Baseline in Body Weight at Week 24","description":"To compare the percentage change from baseline in body weight with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.22","spread":null},{"groupId":"OG001","value":"-3.76","spread":null},{"groupId":"OG002","value":"-0.02","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change From Baseline in 24-hour Continuous Glucose Monitoring (CGM) Mean Value at Week 24","description":"To compare the change from baseline in mean value of 24-hour glucose readings obtained from CGM with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.46","spread":null},{"groupId":"OG001","value":"-10.54","spread":null},{"groupId":"OG002","value":"9.20","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change From Baseline in 24-hour CGM Mean Amplitude of Glycemic Excursion (MAGE) Value at Week 24","description":"To compare the change from baseline in mean amplitude of glucose excursions (MAGE) of 24-hour glucose readings obtained from CGM with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.17","spread":null},{"groupId":"OG001","value":"-9.68","spread":null},{"groupId":"OG002","value":"-0.33","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Percent of 24-hour Glucose Readings Obtained From CGM That Falls Within the Target Range of > 70 mg/dL and <= 180 mg/dL (%) at Week 24","description":"To compare the change from baseline in the percent of 24-hour glucose readings obtained from CGM that falls within the target range of \\>70 mg/dL and \\<=180 mg/dL with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.92","spread":null},{"groupId":"OG001","value":"7.60","spread":null},{"groupId":"OG002","value":"-3.10","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With HbA1c Reduction From Baseline to Week 24 Last Observation Carried Forward (LOCF) >= 0.5% and Without Severe Hypoglycemia Events at Week 24","description":"To compare dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin for the proportion of subjects achieving an HbA1c reduction from baseline to Week 24 visit \\>=0.5% without severe hypoglycemia events","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"111","spread":null},{"groupId":"OG002","value":"54","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":271},"commonTop":["Viral upper respiratory tract infection","Pollakiuria","Upper respiratory tract infection","Headache","Thirst"]}}}